| Drug ID: | Drug16 |
|---|---|
| Drug Name: | Cyclophosphamide |
| CID: | 2907 |
| DrugBank ID: | DB00531 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT03219359 |
| Molecular Formula: | C7H15Cl2N2O2P |
| Molecular Weight: | 261.08 g/mol |
| Isomeric SMILES: | C1CNP(=O)(OC1)N(CCCl)CCCl |
| Synonyms: | cyclophosphamide; 50-18-0; Cytoxan; Cyclophosphamid; Cyclophosphane; Endoxan; Cytophosphan; Procytox; Sendoxan; Clafen |
| Phase 0: | 66 |
| Phase 1: | 1168 |
| Phase 2: | 2257 |
| Phase 3: | 818 |
| Phase 4: | 97 |
| Description: | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt139 | 2907 | Cyclophosphamide | 7150 | TOP1 | Homo sapiens (human) | None | |
| dt140 | 2907 | Cyclophosphamide | 4908 | NTF3 | Homo sapiens (human) | None | |
| dt141 | 2907 | Cyclophosphamide | 7132 | TNFRSF1A | Homo sapiens (human) | None | |
| dt142 | 2907 | Cyclophosphamide | 3458 | IFNG | Homo sapiens (human) | None | |
| dt143 | 2907 | Cyclophosphamide | 4613 | MYCN | Homo sapiens (human) | None | |
| dt144 | 2907 | Cyclophosphamide | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt145 | 2907 | Cyclophosphamide | 5595 | MAPK3 | Homo sapiens (human) | None | |
| dt146 | 2907 | Cyclophosphamide | 1557 | CYP2C19 | Homo sapiens (human) | None | |
| dt147 | 2907 | Cyclophosphamide | 2099 | ESR1 | Homo sapiens (human) | 23611293 | None |
| dt148 | 2907 | Cyclophosphamide | 22809 | ATF5 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT03219359 | Autologous Stem Cell Transplant for Crohn's Disease | PHASE2 | RECRUITING | Aaron Etra | Crohn Disease | PROCEDURE: Autologous stem cell transplant|DRUG: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation with Po…
PMID: 32798657
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Allogeneic hematopoietic stem cell transplantation (HSCT) is performed as a curative treatment for children with nonmalignant diseases, such as bone …
Safety and efficacy of intravenous cyclophosphamide pulse therapy in therapy re…
PMID: 28456770
Year: 2017
Relationship Type:
Treatment
Score: 9.3
A major challenge in the management of persistently active Crohn's disease patient's refractory to treatment regimen following the current guidelines…
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autol…
PMID: 22937722
Year: 2012
Relationship Type:
Treatment
Score: 9.1
BACKGROUND: Despite advances in immunosuppressive therapy, up to 10% of patients with severe Crohn's disease (CD) remain refractory to conventional t…
Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's di…
PMID: 22115387
Year: 2011
Relationship Type:
Treatment
Score: 9.1
BACKGROUND: Sweet's syndrome is a rare extraintestinal manifestation of Crohn's disease that is usually treated by corticosteroids. Cyclophosphamide …
Transformative Results in Giant Pyoderma Gangrenosum with Dexamethasone-cycloph…
PMID: 40069562
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Pyoderma gangrenosum (PG) is a cutaneous ulcerative condition that can present in various forms, including ulcerative, bullous, pustular, vegetative,…
Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Effica…
PMID: 38757210
Year: 2024
Relationship Type:
Association
Score: 6.5
Autologous stem cell transplantation with low-dose cyclophosphamide to improve …
PMID: 38408175
Year: 2024
Relationship Type:
Association
Score: 6.5
Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospe…
PMID: 30018965
Year: 2018
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE To identify the factors associated with first Clostridium difficile infection (CDI) that predict fecal microbiota transplantation (FMT) fo…
Complete resolution of severe ulcerative colitis after haploidentical hematopoi…
PMID: 28581471
Year: 2017
Relationship Type:
Association
Score: 6.3
Pathogenesis of infectious bursal disease in cyclophosphamide-treated chickens
PMID: 18670979
Year: 1992
Relationship Type:
Association
Score: 6.1
BACKGROUND: There has been little investigation of fatigue, a common symptom in inflammatory bowel disease (IBD). The aim of this study was to evalu…
Pulse cyclophosphamide therapy for inflammatory bowel disease
PMID: 16534885
Year: 2006
Relationship Type:
Treatment
Score: 6.1
The central issue for Genetic Analysis Workshop 14 (GAW14) is the question, which is the better strategy for linkage analysis, the use of single-nuc…
Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refr…
PMID: 12584219
Year: 2003
Relationship Type:
Association
Score: 6.1
Using a disease specific instrument to measure the health related quality of life (HRQOL) of patients with inflammatory bowel disease (IBD), it has …
Response of the chicken bursal stroma to treatment with cyclophosphamide and IB…
PMID: 2855388
Year: 1988
Relationship Type:
Treatment
Score: 6.1
Chronic inflammatory T-cell-mediated diseases such as inflammatory bowel disease (IBD) are often treated with immunosuppressants including corticost…